Sun X, Caplan M S, Hsueh W
Department of Pathology, Children's Memorial Hospital, Chicago, IL 60614.
Gut. 1994 Feb;35(2):215-9. doi: 10.1136/gut.35.2.215.
Previous studies have shown that: (a) platelet activating factor induces shock and intestinal injury, (b) exogenous platelet activating factor stimulates synthesis of endogenous platelet activating factor, and (c) tumour necrosis factor alpha and endotoxin synergise to induce shock and bowel injury in animals. These last two effects are largely mediated by platelet activating factor forming phospholipase A2 A2, a key enzyme for platelet activating factor synthesis, was examined in mouse intestine. It was found that tumour necrosis factor alpha and endotoxin synergise to stimulate platelet activating factor forming phospholipase A2 activity in the intestine, as well as platelet activating factor production, and these effects were blocked by pretreatment with platelet activating factor antagonists, SRI-63-441 and WEB 2086. In addition, exogenous platelet activating factor stimulates intestinal phospholipase A2 activity. These results show that tumour necrosis factor alpha and lipopolysaccharide synergistically activate the phospholipase A2 that participates in platelet activating factor formation, and this activation is largely mediated by endogenous platelet activating factor. Furthermore, platelet activating factor itself increases phospholipase A2 activity, suggesting that platelet activating factor induces its own synthesis, probably by phospholipase A2 activation.
(a) 血小板活化因子可诱发休克和肠道损伤;(b) 外源性血小板活化因子可刺激内源性血小板活化因子的合成;(c) 肿瘤坏死因子α和内毒素协同作用可诱发动物休克和肠道损伤。后两种效应很大程度上是由血小板活化因子介导的。在小鼠肠道中检测了参与血小板活化因子合成的关键酶——磷脂酶A2。结果发现,肿瘤坏死因子α和内毒素协同刺激肠道中血小板活化因子形成磷脂酶A2的活性以及血小板活化因子的产生,而血小板活化因子拮抗剂SRI-63-441和WEB 2086预处理可阻断这些效应。此外,外源性血小板活化因子可刺激肠道磷脂酶A2的活性。这些结果表明,肿瘤坏死因子α和脂多糖协同激活参与血小板活化因子形成的磷脂酶A2,且这种激活很大程度上是由内源性血小板活化因子介导的。此外,血小板活化因子本身可增加磷脂酶A2的活性,这表明血小板活化因子可能通过激活磷脂酶A2来诱导自身的合成。